Form 4: Tango Therapeutics Director Receives Stock Options

Tango Therapeutics Director Malte Peters was granted 150,000 stock options with an $8.01 exercise price, vesting over four years.

Summary

• Malte Peters, a Director of Tango Therapeutics, Inc. (TNGX), was granted 150,000 stock options.
• The options have an exercise price of $8.01 per share.
• The transaction date for the grant was November 3, 2025.
• These options will vest in 48 substantially equal monthly installments over a four-year period.
• The first vesting date is scheduled for December 3, 2025.
• The options expire on November 3, 2035.
• Vesting is contingent upon Mr. Peters' continuous service with the Issuer.

Sentiment

Score: 6

Explanation: The filing reports a standard equity compensation event for a director, which is generally viewed as neutral to slightly positive as it aligns management interests with shareholders, without indicating any significant operational or financial changes.

Positives

• The grant of 150,000 stock options to Director Malte Peters aligns his interests with long-term shareholder value creation.
• Equity compensation is a standard practice to incentivize key personnel and retain talent.

Negatives

• No direct negatives are presented in this Form 4 filing.

Risks

• No specific risks are disclosed in this Form 4 filing, which is purely transactional.

Future Outlook

The four-year vesting schedule for the stock options indicates an expectation of continued service from Director Malte Peters and a long-term commitment to the company's performance.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries to attract and retain experienced leadership, aligning their incentives with the company's long-term success and shareholder returns.

Comparison to Industry Standards

• The grant of 150,000 stock options with a four-year vesting schedule is a standard form of equity compensation for directors in the biotech sector, comparable to practices seen at companies like Moderna or BioNTech for their non-executive directors, aiming to incentivize long-term value creation.

Related Party Transactions

• The grant of stock options to Director Malte Peters constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value.
• Management: Reinforces the commitment of a key director.

Next Steps

• The stock options will vest monthly over the next four years, contingent on Malte Peters' continuous service.

Key Dates

Keywords

Tango Therapeutics, TNGX, Malte Peters, Director, Stock Options, Equity Grant, Insider Transaction, Compensation, Form 4, SEC Filing